Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026GlobeNewsWire • 12/18/25
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 12/09/25
Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical UpdateGlobeNewsWire • 11/12/25
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051GlobeNewsWire • 10/24/25
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination TherapiesGlobeNewsWire • 10/15/25
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/14/25
Aprea Therapeutics to Present at H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 08/28/25
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical UpdateGlobeNewsWire • 08/12/25
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer CenterGlobeNewsWire • 06/25/25
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical UpdateGlobeNewsWire • 05/14/25
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 TrialGlobeNewsWire • 03/31/25
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateGlobeNewsWire • 03/25/25
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)GlobeNewsWire • 03/11/25
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer TherapeuticsGlobeNewsWire • 02/05/25
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path ForwardGlobeNewsWire • 12/11/24
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom FisherZacks Investment Research • 11/13/24
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/07/24
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and TherapeuticsGlobeNewsWire • 10/23/24
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and TherapeuticsGlobeNewsWire • 10/10/24
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical DevelopmentGlobeNewsWire • 10/09/24
UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment ConferenceGlobeNewsWire • 09/09/24
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment ConferenceGlobeNewsWire • 09/09/24
Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/12/24